rociletinib and tolebrutinib share 3 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.250 means 25% of the combined target set is bound by both compounds. The IDF-weighted score of 0.227 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do rociletinib and tolebrutinib have in common?
rociletinib and tolebrutinib share 3 molecular targets with a Jaccard similarity of 25%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can rociletinib and tolebrutinib be combined?
rociletinib and tolebrutinib share 3 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: rociletinib or tolebrutinib?
In the BiohacksAI corpus: rociletinib has 0 PubMed-indexed studies, tolebrutinib has 0 studies.